about
Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study.The Life Cycle of Health Technologies. Challenges and Ways Forward.Burden of stroke in Italy: an economic model highlights savings arising from reduced disability following thrombolysis.Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women.Differences in Effectiveness among Devices for Endovascular Thrombectomy in Patients with Acute Ischemic Stroke.Rituximab biosimilar in rheumatoid arthritis: an enhanced-evidence assessment to evaluate equivalence with the originator based on network meta-analysis.Rituximab biosimilar evaluated by network meta-analysis.Comorbidity, Polytherapy, and Drug Interactions in a Neurological Context: An Example of a Multidisciplinary Approach to Promote the Rational Use of Drugs.CAPACITY BUILDING IN AGENCIES FOR EFFICIENT AND EFFECTIVE HEALTH TECHNOLOGY ASSESSMENT.Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy.Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs.Promoting the use of Markovian simulation models to study outcomes of thrombectomy after acute ischemic stroke.Safety of intravitreal injections: Non-inferiority of bevacizumab compared with ranibizumabTisagenlecleucel in Non-Hodgkin Lymphoma: The Restricted Mean Survival Time as a Tool for Estimating Progression-Free Life Expectancy Better than the MedianHTA Metro Map: a patient centred model for optimizing the decision making processCAR-T Treatment: Determining the Survival Gain in Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaTyrosine-kinase inhibitor discontinuation in chronic myeloid leukaemia after deep molecular response: a meta-analysis with meta-regressionAnalysis of Survival Curves: Statistical Methods Accounting for the Presence of Long-Term SurvivorsTrastuzumab biosimilar in metastatic breast cancer: Evaluating equivalence with originator using network meta-analysis
P50
Q36343040-21C0DF4F-EEB1-495F-8A09-7A15B98E6FF2Q37601340-7094B532-9904-4BFD-A2B1-95AD3CC0DDA3Q41100489-8EB6D3CE-A135-4761-B2FE-91BCBC7676DDQ41633470-520784DF-484A-4CE5-9EF1-20492B1EC357Q41869057-87C31E72-5A0F-4672-9D25-7D18E9F40D8EQ42062698-9B4CCA8F-9391-4393-B3BF-A9DF3EE9B0B9Q47151262-7A6F2A05-6215-40CF-BC22-E47D9F977D38Q47247257-4290CB3D-8D2D-4DB8-8CFD-FB09F531FC48Q47267534-C78F5D17-4218-4A88-AE7F-20CCA09F1012Q49996815-55FDADAA-E1FA-4FE4-B83A-D1CFCBAC4169Q50163806-9E3A0680-8529-461E-A0AD-76CE36112BB1Q50244860-F2222D1B-66A5-4AA7-93E1-45CD10A3D68DQ58114397-789D5776-73A6-4D53-BD63-CF79A3E2D7DEQ89780494-9FD48B03-1944-4A6D-87AA-0EDECEA6CE6BQ90251344-05DA06BE-33F5-4094-95D1-DB565BAB49B5Q90336381-50816109-20A7-4D80-8737-EA5C61BDAE95Q92959210-5BFE0FE0-DFDE-41E1-B596-A05CC1A1D75EQ92972397-83782BB8-6741-4294-8350-BBCF6BFF3552Q95380570-2FADBFF4-B541-46D3-9930-A4E8E265C725
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marco Chiumente
@ast
Marco Chiumente
@en
Marco Chiumente
@es
Marco Chiumente
@fr
Marco Chiumente
@nl
Marco Chiumente
@sl
type
label
Marco Chiumente
@ast
Marco Chiumente
@en
Marco Chiumente
@es
Marco Chiumente
@fr
Marco Chiumente
@nl
Marco Chiumente
@sl
prefLabel
Marco Chiumente
@ast
Marco Chiumente
@en
Marco Chiumente
@es
Marco Chiumente
@fr
Marco Chiumente
@nl
Marco Chiumente
@sl
P1053
O-1681-2017
P106
P1153
56453437100
P21
P2798
P31
P3829
P496
0000-0002-0943-6746